Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemtuzumab vs Liposomal Daunorubicin vs Topotecan Regimens in Relapsed/Refractory AML
NCT00005962Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Oct 2000
- Primary completion
- Oct 2005
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) comparing Gemtuzumab + Cytarabine, Liposomal Daunorubicin + Cytarabine and Cyclophosphamide + Cytarabine + Topotecan (3 arms). Primary endpoints: Complete Response Rate and Complete Response without Full Platelet Recovery Rate. Started Oct 2000; status: completed.
02
Drugs
gemtuzumab ozogamicindaunorubicintopotecan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00005962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005962.